Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

doi:10.1200/JCO.2010.32.9110

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jun 2011

Xu Chun-Fang, Bing Nan X, Ball Howard A, Rajagopalan Dilip, Sternberg Cora N, Hutson Thomas E, de Souza Paul, Xue Zhengyu G, McCann Lauren, King Karen S, Ragone Leigh J, Whittaker John C, Spraggs Colin F, Cardon Lon R, Mooser Vincent E, Pandite Lini N

Abstract excerpt

PURPOSE: Pazopanib, an oral angiogenesis inhibitor, is approved for the treatment of advanced renal cell carcinoma (RCC). Response to pazopanib monotherapy varies between patients, and no validated biomarkers predictive of treatment outcome have been identified. We tested the hypothesis that this variability is partially dependent on germline genetic variants that may affect pazopanib exposure or angiogenesis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Renal Cell

Share to Clinical Trials, Phase II as Topic

Share to Cross-Over Studies

Share to Indazoles

Share to Multicenter Studies as Topic

Share to Neovascularization, Physiologic

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed

Identifiers

PMID: 21576632
DOI: 10.1200/JCO.2010.32.9110

Genes

VEGFA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.PMID 21576632Read ↗

The role of pharmacogenomics in metastatic renal cell carcinoma.Semantic proximity Read ↗

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.Semantic proximity Read ↗

MicroRNA target site polymorphisms in the VHL-HIF1α pathway predict renal cell carcinoma risk.Semantic proximity Read ↗

Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.Semantic proximity Read ↗

Anti-Angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-CarcinomaSemantic proximity Read ↗

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.Semantic proximity Read ↗

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.Semantic proximity Read ↗

Commentary on "Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study." Schutz FA, Pomerantz MM, Gray KP, Atkins MB, Rosenberg JE, Hirsch MS, McDermott DF, Lampron ME, Lee GS, Signoretti S, Kantoff PW, Freedman ML, Choueiri TK, Dana-Farber Cancer Institute, Boston, MA 02115.: Lancet Oncol 2013;14(1):81-87. [Epub 2012 Dec 7]. doi: 10.1016/S1470-2045(12)70517-X. Erratum in, Lancet Oncol 2013;14(3):e89.Semantic proximity Read ↗

Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial.Semantic proximity Read ↗

Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib.Semantic proximity Read ↗

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.Semantic proximity Read ↗

Molecular biomarkers in advanced renal cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.